

ASX Announcement 1 March 2022

Resignation of Non-Executive Director – Dr John Chiplin

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises that Non-Executive Director, Dr John Chiplin has resigned from the Company's Board, effective immediately.

Dr Chiplin joined the Board of Regeneus as Non-Executive Director in April 2019. Dr Chiplin is Managing Director of Newstar Ventures Ltd and brought a wealth of operational, investment and transaction experience to the Board of Regeneus.

The Board of Regeneus would like to thank Dr Chiplin for his contribution to Regeneus, assisting the Company in delivering on its commitment to commercialise its lead stem cell technology platform Progenza to commercialisation.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Chairman and Company Secretary of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 03 8866 1200
E: WE-AURegeneus@we-worldwide.com